Helsinn Healthcare S.A.
- Address
- Via Pian Scairolo 9
Sponsor Overview
Specializations
Chemotherapy-induced nausea and vomiting in paediatric oncology
Helsinn Healthcare S.A. supports clinical research in paediatric cancer settings focused on preventing chemotherapy-induced nausea and vomiting during both single-day and multi-day high-emetogenic chemotherapy. The work centers on intravenous antiemetic regimens that combine netupitant and palonosetron, with attention to symptom control across treatment cycles in children and adolescents.
- Delayed-phase emesis
- Intravenous antiemetic therapy
- Paediatric oncology supportive care
Clinical interest extends to repeated administration, treatment tolerability, and comparison with established antiemetic combinations used in oncology care.
Pharmacokinetics and exposure assessment
The sponsor’s research includes evaluation of fosnetupitant and netupitant exposure in paediatric and adult populations, with a focus on confirming expected systemic levels after intravenous administration. This area reflects interest in how the combination product behaves across age groups and body sizes, including very young patients.
- Drug exposure
- Paediatric pharmacology
- Systemic absorption
These studies support development of antiemetic therapy with age-appropriate pharmacological performance.
Safety and tolerability of repeated treatment
Another research focus is the assessment of safety and tolerability during repeated dosing of intravenous NEPA in paediatric patients receiving chemotherapy. The clinical interest lies in maintaining control of emesis while monitoring treatment acceptability over multiple administration days.
- Repeated administration
- Tolerability assessment
- Oncology supportive treatment
This domain is closely tied to practical use in children undergoing intensive cancer therapy.
Bioequivalence of oral antiemetic formulations
Helsinn Healthcare S.A. also funds research in healthy volunteers to compare an oral suspension of the netupitant/palonosetron combination with the corresponding hard capsule formulation. The therapeutic interest is in confirming comparable performance between oral dosage forms of the same antiemetic combination.
- Oral suspension
- Hard capsule formulation
- Combination antiemetic product
This area supports formulation development for use in patients who may benefit from alternative oral delivery options.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Bioequivalence Study of Netupitant/Palonosetron Oral Suspension versus Hard Capsules in Healthy Volunteers |  Germany | Not Yet Recruiting |
| Bioequivalence Study of Netupitant/Palonosetron Oral Suspension Versus Capsules in Healthy Volunteers: An Open-Label, Randomized, Replicative Design | Germany | Not Recruiting |
| Evaluation of Intravenous Fosnetupitant/Palonosetron for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients Undergoing Highly Emetogenic Chemotherapy |  Greece Poland Romania | Recruiting |
Data & Insights
This sponsor works with 5 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 15 sites across their trial portfolio.
Therapeutic Focus
- 1.Not possible to specify2 trials220 other sponsors
- 2.Pathological Conditions, Signs and Symptoms1 trial91 other sponsors
Partnered Research Centres
15 centres- Address
- Grenadierstrasse 1, Neckarstadt, 68167 Mannheim
- Address
- Soseaua Fundeni 258, 022328 Bucharest
- Address
- Soseaua Fundeni 252, 022328 Bucharest
- Address
- Ul Marcina Kasprzaka 17 A, 01-211 Warsaw
- Address
- Aleja Dzieci Polskich 20, 04-730 Warsaw
- Address
- Thivon Papadiamantopoulou, 115 27 Athens
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Helsinn Healthcare S.A..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.